Hypermethylation of the RECK gene predicts poor prognosis in oral squamous cell carcinomas

Oral Oncology

Volumn 44, Issue 11, 2008, Pages 1052-1058

  Long, Nguyen Khanh ^a   Kato, Keizo ^a   Yamashita, Tomomi ^a   Makita, Hiroki ^a   Toida, Makoto ^a   Hatakeyama, Daijiro ^a   Hara, Akira ^a   Mori, Hideki ^a   Shibata, Toshiyuki ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

Hypermethylation; Oral cancer; Prognosis; RECK

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MALE; METHYLATION; MOUTH CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RECK GENE; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DNA METHYLATION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; JAPAN; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; PROGNOSIS;

EID: 53849138003     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.02.004     Document Type: Article

References (31)

1. In: Shah J.P., Johnson N.W., and Batsakis J.G. (Eds). Oral cancer (2003), Martin Dunitz Press, London 3-98
2. In: Barnes L., Eveson J.W., Reichart P., and Sidransky D. (Eds). World Health Organization classification of tumours. Pathology and genetics of head and neck tumours (2005), IARC Press, Lyon 168-175
3. Kulkarni V., and Saranath D. Concurrent hypermethylation of multiple regulatory genes in chewing tobacco associated oral squamous cell carcinomas and adjacent normal tissues. Oral Oncol 40 2 (2004) 145-153
4. Ishida E., Nakamura M., Ikuta M., Shimada K., Matsuyoshi S., Kirita T., et al. Promotor hypermethylation of p14ARF is a key alteration for progression of oral squamous cell carcinoma. Oral Oncol 41 6 (2005) 614-622
5. Takahashi C., Sheng Z., Horan T.P., Kitayama H., Maki M., Hitomi K., et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA 95 22 (1998) 13221-13226
6. Oh J., Takahashi R., Kondo S., Mizoguchi A., Adachi E., Sasahara R.M., et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107 6 (2001) 789-800
7. Noda M., Oh J., Takahashi R., Kondo S., Kitayama H., and Takahashi C. RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metast Rev 22 2-3 (2003) 167-175
8. Clark J.C., Thomas D.M., Choong P.F., and Dass C.R. RECK a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metast Rev 26 3-4 (2007) 675-683
9. Cho C.Y., Wang J.H., Chang H.C., Chang C.K., and Hung W.C. Epigenetic inactivation of the metastasis suppressor RECK enhances invasion of human colon cancer cells. J Cell Physiol 213 1 (2007) 65-69
10. Chang H.C., Cho C.Y., and Hung W.C. Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer. Cancer Sci 98 2 (2007) 169-173
11. Chang H.C., Cho C.Y., and Hung W.C. Silencing of the metastasis suppressor RECK by RAS oncogene is mediated by DNA methyltransferase 3b-induced promoter methylation. Cancer Res 66 17 (2006) 8413-8420
12. Jin Z., Mori Y., Yang J., Sato F., Ito T., Cheng Y., et al. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma. Oncogene 26 43 (2007) 6332-6340
13. Sun D., Zhang Z., Van do N., Huang G., Ernberg I., and Hu L. Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker. Oral Oncol 43 1 (2007) 82-87
14. Brock M.V., Gou M., Akiyama Y., Muller A., Wu T.T., Montgomery E., et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 9 8 (2003) 2912-2919
15. Kato K., Hara A., Kuno T., Mori H., Yamashita T., Toida M., et al. Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. J Cancer Res Clin Oncol 132 11 (2006) 735-743
16. Eads C.A., Lord R.V., Kurumboor S.K., Wickramasinghe K., Skinner M.L., Long T.I., et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 60 18 (2000) 5021-5026
17. Martone T., Gillio-Tos A., De Marco L., Fiano V., Maule M., Cavalot A., et al. Association between hypermethylated tumor and paired surgical margins in head and neck squamous cell carcinomas. Clin Cancer Res 13 17 (2007) 5089-5094
18. Chang H.C., Liu L.T., and Hung W.C. Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. Cell Signal 16 6 (2004) 675-679
19. Liu L.T., Chang H.C., Chiang L.C., and Hung W.C. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 63 12 (2003) 3069-3072
20. Hsu M.C., Chang H.C., and Hung W.C. HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. J Biol Chem 281 8 (2006) 4718-4725
21. Kato K., Hara A., Kuno T., Kitaori N., Huilan Z., Mori H., et al. Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity. J Cancer Res Clin Oncol 131 6 (2005) 340-346
22. Takemoto N., Tada M., Hida Y., Asano T., Cheng S., Kuramae T., et al. Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung. Lung Cancer 58 3 (2007) 376-383
23. Song S.Y., Son H.J., Nam E., Rhee J.C., and Park C. Expression of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in gastric cancer. Eur J Cancer 42 1 (2006) 101-108
24. Takenaka K., Ishikawa S., Yanagihara K., Miyahara R., Hasegawa S., Otake Y., et al. Prognostic significance of reversion-inducing cysteine-rich protein with Kazal motifs expression in resected pathologic stage IIIA N2 non-small-cell lung cancer. Ann Surg Oncol 12 10 (2005) 817-824
25. Takeuchi T., Hisanaga M., Nagao M., Ikeda N., Fujii H., Koyama F., et al. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res 10 16 (2004) 5572-5579
26. Masui T., Doi R., Koshiba T., Fujimoto K., Tsuji S., Nakajima S., et al. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clin Cancer Res 9 5 (2003) 1779-1784
27. Span P.N., Sweep C.G., Manders P., Beex L.V., Leppert D., and Lindberg R.L. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma. Cancer 97 11 (2003) 2710-2715
28. Furumoto K., Arii S., Mori A., Furuyama H., Gorrin Rivas M.J., et al. RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing-cysteine-rich protein with Kazal motifs. Hepatology 33 1 (2001) 189-195
29. Szyf M., Pakneshan P., and Rabbani S.A. DNA demethylation and cancer: therapeutic implications. Cancer Lett 211 2 (2004) 133-143
30. Ogi K., Toyota M., Ohe-Toyota M., Tanaka N., Noguchi M., Sonoda T., et al. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res 8 10 (2002) 3164-3171
31. Maeda G., Chiba T., Kawashiri S., Satoh T., and Imai K. Epigenetic inactivation of IkappaB Kinase-alpha in oral carcinomas and tumor progression. Clin Cancer Res 13 17 (2007) 5041-5047